Deepak R. Rao

Array ( [id] => 17959951 [patent_doc_number] => 20220340531 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-27 [patent_title] => AROMATIC ALDEHYDES WITH SUSTAINED AND ENHANCED IN VITRO AND IN VIVO PHARMACOLOGIC ACTIVITY TO TREAT SICKLE CELL DISEASE [patent_app_type] => utility [patent_app_number] => 17/846101 [patent_app_country] => US [patent_app_date] => 2022-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15806 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17846101 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18339453 [patent_doc_number] => 20230131402 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-27 [patent_title] => SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/831544 [patent_app_country] => US [patent_app_date] => 2022-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17197 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17831544 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18093077 [patent_doc_number] => 20220411418 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => CDGSH IRON SULFUR DOMAIN 2 ACTIVATORS AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/824547 [patent_app_country] => US [patent_app_date] => 2022-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15332 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17824547 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18733410 [patent_doc_number] => 11802133 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-31 [patent_title] => Heterocyclic compounds as monoacylglycerol lipase inhibitors [patent_app_type] => utility [patent_app_number] => 17/749496 [patent_app_country] => US [patent_app_date] => 2022-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50540 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17749496 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18153045 [patent_doc_number] => 11566005 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-31 [patent_title] => Highly pure phentolamine mesylate and methods for making same [patent_app_type] => utility [patent_app_number] => 17/747656 [patent_app_country] => US [patent_app_date] => 2022-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 17824 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17747656 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18329181 [patent_doc_number] => 11634409 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-25 [patent_title] => Compounds for the treatment of BRAF-associated diseases and disorders [patent_app_type] => utility [patent_app_number] => 17/745346 [patent_app_country] => US [patent_app_date] => 2022-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 103607 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17745346 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18887684 [patent_doc_number] => 11866445 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-09 [patent_title] => Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors [patent_app_type] => utility [patent_app_number] => 17/663557 [patent_app_country] => US [patent_app_date] => 2022-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20755 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17663557 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18057910 [patent_doc_number] => 20220388996 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-08 [patent_title] => METHODS OF MAKING A MODULATOR OF HEMOGLOBIN [patent_app_type] => utility [patent_app_number] => 17/744525 [patent_app_country] => US [patent_app_date] => 2022-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28311 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17744525 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18620365 [patent_doc_number] => 11753393 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-09-12 [patent_title] => Dihydroorotate dehydrogenase inhibitors [patent_app_type] => utility [patent_app_number] => 17/742606 [patent_app_country] => US [patent_app_date] => 2022-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 69874 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17742606 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19257955 [patent_doc_number] => 12017996 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-25 [patent_title] => Substituted quinolines and formulations thereof [patent_app_type] => utility [patent_app_number] => 17/740364 [patent_app_country] => US [patent_app_date] => 2022-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 13411 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17740364 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18272245 [patent_doc_number] => 20230093487 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-23 [patent_title] => VASODILATORS FOR TREATMENT OF HEART FAILURE [patent_app_type] => utility [patent_app_number] => 17/739629 [patent_app_country] => US [patent_app_date] => 2022-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7984 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17739629 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18444510 [patent_doc_number] => 11680068 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-20 [patent_title] => Compounds useful as RET inhibitors [patent_app_type] => utility [patent_app_number] => 17/738278 [patent_app_country] => US [patent_app_date] => 2022-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22937 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17738278 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18910326 [patent_doc_number] => 11873295 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-16 [patent_title] => Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease [patent_app_type] => utility [patent_app_number] => 17/734705 [patent_app_country] => US [patent_app_date] => 2022-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54114 [patent_no_of_claims] => 125 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 274 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17734705 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19180983 [patent_doc_number] => 11987564 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-05-21 [patent_title] => PTPRD inhibitors and uses thereof [patent_app_type] => utility [patent_app_number] => 17/734897 [patent_app_country] => US [patent_app_date] => 2022-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28160 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 132 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17734897 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17929675 [patent_doc_number] => 20220324800 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-13 [patent_title] => SARS-3CL PROTEASE INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/657454 [patent_app_country] => US [patent_app_date] => 2022-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23682 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17657454 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19536696 [patent_doc_number] => 12129237 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-29 [patent_title] => Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith [patent_app_type] => utility [patent_app_number] => 17/707471 [patent_app_country] => US [patent_app_date] => 2022-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67985 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 226 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17707471 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18187493 [patent_doc_number] => 11578061 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-14 [patent_title] => Inhibitors of LRRK2 kinase [patent_app_type] => utility [patent_app_number] => 17/702600 [patent_app_country] => US [patent_app_date] => 2022-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39429 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 200 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17702600 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18285503 [patent_doc_number] => 20230100975 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-30 [patent_title] => DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 17/655843 [patent_app_country] => US [patent_app_date] => 2022-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35690 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 213 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17655843 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17851848 [patent_doc_number] => 20220281890 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-08 [patent_title] => PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUG THEREOF [patent_app_type] => utility [patent_app_number] => 17/689194 [patent_app_country] => US [patent_app_date] => 2022-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37862 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17689194 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18964132 [patent_doc_number] => 11897882 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-13 [patent_title] => Tricyclic crbn ligands and uses thereof [patent_app_type] => utility [patent_app_number] => 17/679496 [patent_app_country] => US [patent_app_date] => 2022-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 80117 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 483 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17679496 [rel_patent_id] =>[rel_patent_doc_number] =>)